论文部分内容阅读
针对胶质瘤细胞表面的特异性标记物进行靶向治疗是目前肿瘤治疗的一个新途径,国外文献报道将免疫毒素与肿瘤细胞表面特异性标记物的单克隆抗体或其配体结合构建融合蛋白可用于肿瘤治疗。白细胞介素13受体(interleukin-13 re-ceptor,IL-13R)是在胶质瘤表面表达的特异性的分子标记物,并与胶质瘤的恶性度呈正相关。国外学者已开展了应用IL-13R在脑胶质瘤靶向治疗中的临床试验研究,笔者对这方面的最新研究进展进行简要综述。
Targeted treatment of specific markers on the surface of glioma cells is a new way of cancer treatment, foreign literature reports the immunotoxin and tumor cell surface markers specific monoclonal antibody or its ligand to create a fusion protein Can be used for cancer treatment. Interleukin-13 re-ceptor (IL-13R) is a specific molecular marker expressed on the surface of glioma and positively correlates with the malignancy of glioma. Foreign scholars have carried out clinical trials on the use of IL-13R in the targeted therapy of gliomas, and the author reviews the latest research progress in this area.